| ID | 10052 |
| Vaccine Name | Covovax (Nuvaxovid) |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Subunit vaccine |
| Vaccine Status | Approved |
| Manufacturer | Novavax Inc. |
| Year of Manufacturing | 2020 |
| Manufacturing Country | USA |
| Age | NA |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | Recombinant nanoparticle prefusion spike protein formulated with Matrix adjuvant |
| Approving Organisation | EMA, WHO |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | TAK-019, SARS-CoV-2 rS, NVX-CoV2373 |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf |
| Additional Links | https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know
|